9TBM

From KRASG12D to pan-KRAS inhibitors

This is a non-PDB format compatible entry.

Summary for 9TBM

• Entry DOI: 10.2210/pdb9tbm/pdb
• Descriptor: Isoform 2B of GTPase KRas, MAGNESIUM ION, GUANOSINE-5'-DIPHOSPHATE, ... (5 entities in total)
• Functional Keywords: kras, gtpase, human, regulation, cell-proliferation, signaling protein
• Biological source: Homo sapiens (human)
• Total number of polymer chains: 3
• Total formula weight: 66451.63

Authors

Cleasby, A.,Day, P. (deposition date: 2025-11-20, release date: 2026-04-22, Last modification date: 2026-05-06)

Primary citation

Ma, X.,Sloman, D.L.,Henderson, T.J.,Bennett, D.J.,Chessari, G.,Day, P.J.,Duggal, R.,Edelstein, E.,Gathiaka, S.,Hoover, A.,Howard, S.,Kawamura, S.,Kobayakawa, Y.,Lacey, B.M.,Lyons, T.W.,Mansueto, M.S.,Miller, R.,Mizuarai, S.,Munsell, E.V.,O'Reilly, M.,Oshima, T.,Otte, R.D.,Palani, A.,Rees, D.C.,Sagara, T.,Sather, A.,Schopf, P.,Shibata, K.,Shikata, Y.,Solban, N.,Venkataraman, S.,Su, D.,Swaminathan, U.,Ye, Y.,Stoeck, A.,Han, Y.
From KRAS G12D to Pan-KRAS Inhibitors─A Journey Enabled by Synthetic Innovation and Structure-Based Drug Design.
J.Med.Chem., 69:9215-9241, 2026

PubMed Abstract: KRAS, a significant oncology target, has been challenging to develop drugs for until recent discoveries of KRAS mutant-specific covalent inhibitors, including MK-1084. This article describes efforts toward the discovery of KRAS mutant-specific inhibitors and how synthetic innovations and structure-based drug design were utilized to facilitate the discovery of pan-KRAS inhibitors.

PubMed: 41954203
DOI: 10.1021/acs.jmedchem.5c03662

Experimental method

X-RAY DIFFRACTION (1.6 Å)